嗜酸性粒細胞氣喘市場規模、佔有率和成長分析：按藥物類別、給藥途徑、患者人口統計特徵、分銷和採購管道、醫療保健環境和地區分類－2026-2033年產業預測

2024 年全球嗜酸性粒細胞氣喘市場價值為 11.5 億美元，預計到 2025 年將成長至 12.1 億美元，到 2033 年將成長至 18.1 億美元，在預測期（2026-2033 年）內複合年成長率為 5.16%。

全球嗜酸性粒細胞氣喘市場主要集中於治療以氣道嗜酸性粒細胞計數升高為特徵的重度氣喘。儘管接受了傳統治療，但仍有大量患者反覆出現氣喘急性發作，這促使製藥公司增加對生物製藥（如美泊利單抗和貝那利單抗）的投資。首個抗IL-5單株抗體問世後，市場成長加速，保險公司也因此加強了報銷機制，以改善病患的用藥途徑。日益嚴重的都市區空氣污染和人口老化加重了重度氣喘的負擔，推動了精準醫療的需求。隨著越來越多的患者獲得生物製藥的健保覆蓋，製藥公司正在投資研發針對白細胞介素路徑的新一代療法。這些不斷變化的市場環境為北美和歐洲以外的地區，特別是診斷技術日益先進的地區，創造了市場擴張的機會。

全球嗜酸性粒細胞氣喘市場的成長要素

全球嗜酸性粒細胞氣喘市場正受到公眾和醫療專業人員對該疾病嚴重性認知不斷提高的顯著影響。這種認知的提升促使疾病得到早期診斷，治療方案也更加積極，越來越多的患者符合接受先進療法的條件。教育活動和最新的醫療指南強調了嗜酸性粒細胞氣喘的獨特特徵，鼓勵醫療專業人員考慮採取針對性的干預措施。隨著醫生對嗜酸性粒細胞發炎的識別能力不斷提高，呼吸系統疾病中專用生物製藥和療法的應用將會激增。此趨勢也將刺激製藥企業加大研發投入，豐富產品線，並推動市場成長。

全球嗜酸性粒細胞氣喘市場的限制因素

由於生物製藥價格高帶來的經濟障礙，全球嗜酸性粒細胞氣喘市場的成長面臨嚴峻挑戰。保險公司、醫療機構和患者都面臨嚴格的報銷要求，通常需要提供嗜酸性粒細胞計數升高或常規治療失敗的證明。這些嚴格的先決條件可能會阻礙患者及時獲得必要的治療，並減少處方箋總量。因此，市場對更具成本效益的替代療法的需求日益成長，減緩了新療法進入市場的步伐。即使這些療法在臨床上取得成功，製造商的收入成長也可能受到限制，導致市場環境謹慎，臨床接受度有限。

嗜酸性粒細胞氣喘的全球市場趨勢

隨著伴隨診斷和患者分層等醫學技術的進步，全球嗜酸性粒細胞氣喘市場正經歷著向個人化生物製藥療法的顯著轉變。醫生擴大利用生物標記、疾病嚴重程度和合併症模式來選擇標靶治療，從而改善治療效果並最大限度地減少不必要的副作用。這種個人化方法增強了醫病信任，提高了患者的治療順從性。此外，這種方法也促使製藥公司開發與這些個人化治療方案相符的專用製劑，以適應全球多樣化的醫療保健環境。因此，預計該市場將持續成長，最終改善患者的治療效果，並嗜酸性粒細胞氣喘。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球嗜酸性粒細胞氣喘市場規模：依藥物分類

• 生物製藥
  • 抗IL-5生物製藥
  • 抗IL-5R生物製藥
  • 抗IL-4R生物製藥
• 皮質類固醇
• 支氣管擴張劑
• 白三烯調節劑

全球嗜酸性粒細胞氣喘市場規模：依給藥途徑分類

• 皮下注射
• 靜脈輸液
• 口服
• 吸入

全球嗜酸性粒細胞氣喘市場規模：依患者特徵分類

• 兒童患者
• 成年患者
• 老年患者

全球嗜酸性粒細胞氣喘市場規模：依分銷及採購管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球嗜酸性粒細胞氣喘市場規模：依醫療保健服務環境分類

• 醫院和專科診所
• 家庭醫療保健環境

全球嗜酸性粒細胞氣喘市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline plc
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Regeneron Pharmaceuticals Inc.
• Novartis AG
• Roche Holding AG
• Merck & Co. Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Chiesi Farmaceutici SpA
• Shionogi & Co. Ltd.
• Kiniksa Pharmaceuticals Ltd.
• Pieris Pharmaceuticals Inc.
• AB Science
• Gossamer Bio Inc.
• Knopp Biosciences
• Synairgen plc
• 4D Pharma plc

結論與建議

Global Eosinophilic Asthma Market size was valued at USD 1.15 Billion in 2024 and is poised to grow from USD 1.21 Billion in 2025 to USD 1.81 Billion by 2033, growing at a CAGR of 5.16% during the forecast period (2026-2033).

The global eosinophilic asthma market focuses on therapies for a severe form of asthma characterized by elevated eosinophil levels in the airways. There remains a significant unmet clinical need for patients experiencing recurrent exacerbations despite conventional treatments, prompting pharmaceutical investments in biologics like mepolizumab and benralizumab. Following the introduction of the first anti-IL-5 monoclonal antibody, market growth surged, resulting in enhanced reimbursement frameworks by payers to improve patient access. Increased urban pollution and an aging population are intensifying the burden of severe asthma, leading to a heightened demand for precision medicine. As more patients gain insurance coverage for biologics, drug makers are investing in next-generation therapies targeting interleukin pathways. This evolving landscape offers opportunities for market expansion beyond North America and Europe into regions with improved diagnostics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Eosinophilic Asthma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Eosinophilic Asthma Market Segments Analysis

Global eosinophilic asthma market is segmented by drug product class, route of administration, patient demographics, distribution procurement channel, care setting environment and region. Based on drug product class, the market is segmented into Biologic Therapies, Corticosteroids, Bronchodilators and Leukotriene Modifiers. Based on route of administration, the market is segmented into Subcutaneous Injection, Intravenous Infusion, Oral Ingestion and Inhalation. Based on patient demographics, the market is segmented into Pediatric Patients, Adult Patients and Geriatric Patients. Based on distribution procurement channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on care setting environment, the market is segmented into Hospitals and Specialty Clinics and Home Healthcare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Eosinophilic Asthma Market

The global market for eosinophilic asthma is significantly influenced by the heightened awareness among both the public and healthcare professionals regarding the serious nature of the condition. This awareness has led to earlier diagnoses and more proactive treatment approaches, increasing the patient population eligible for advanced therapies. Educational initiatives and updated medical guidelines highlight the unique characteristics of eosinophilic asthma, prompting healthcare providers to consider targeted interventions. As physicians become more adept at identifying eosinophilic inflammation, there will be a surge in the application of specialized biologics and therapeutic practices within respiratory care. This trend also attracts greater pharmaceutical investment in research, enhancing the pipeline and driving growth in the market.

Restraints in the Global Eosinophilic Asthma Market

The growth of the Global Eosinophilic Asthma market faces significant challenges due to financial barriers associated with the high pricing of biologic treatments. Insurers, providers, and patients encounter strict reimbursement requirements, which often necessitate proof of elevated eosinophil levels and prior treatment failures. These stringent prerequisites can impede timely access to necessary therapies and reduce the overall number of prescriptions written. Consequently, there is a heightened search for more cost-effective alternatives, resulting in slower adoption rates within the market. Even when these treatments demonstrate clinical success, manufacturers may experience constrained revenue growth, fostering a cautious market landscape with limited broader clinical acceptance.

Market Trends of the Global Eosinophilic Asthma Market

The Global Eosinophilic Asthma market is experiencing a significant shift toward personalized biologic therapies, as medical advancements in companion diagnostics and patient stratification gain traction. Physicians are increasingly utilizing biomarker profiles, disease severity, and comorbidity patterns to select targeted treatments, enhancing therapeutic efficacy and minimizing unnecessary side effects. This tailored approach fosters stronger clinician-patient relationships and boosts treatment adherence. Furthermore, it encourages pharmaceutical manufacturers to innovate specialized formulations that align with these individualized regimens, catering to diverse global healthcare environments. As a result, the market is poised for sustainable growth, ultimately leading to improved patient outcomes and enhanced management of eosinophilic asthma.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Eosinophilic Asthma Market Size by Drug Product Class & CAGR (2026-2033)

• Market Overview
• Biologic Therapies
  • Anti-IL-5 Biologics
  • Anti-IL-5R Biologics
  • Anti-IL-4R Biologics
• Corticosteroids
• Bronchodilators
• Leukotriene Modifiers

Global Eosinophilic Asthma Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Subcutaneous Injection
• Intravenous Infusion
• Oral Ingestion
• Inhalation

Global Eosinophilic Asthma Market Size by Patient Demographics & CAGR (2026-2033)

• Market Overview
• Pediatric Patients
• Adult Patients
• Geriatric Patients

Global Eosinophilic Asthma Market Size by Distribution Procurement Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Eosinophilic Asthma Market Size by Care Setting Environment & CAGR (2026-2033)

• Market Overview
• Hospitals and Specialty Clinics
• Home Healthcare Settings

Global Eosinophilic Asthma Market Size & CAGR (2026-2033)

• North America (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • US
  • Canada
• Europe (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Product Class, Route of Administration, Patient Demographics, Distribution Procurement Channel, Care Setting Environment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiniksa Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pieris Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gossamer Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Knopp Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synairgen plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 4D Pharma plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations